RU2227749C2 - Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета - Google Patents

Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета

Info

Publication number
RU2227749C2
RU2227749C2 RU2001120726/15A RU2001120726A RU2227749C2 RU 2227749 C2 RU2227749 C2 RU 2227749C2 RU 2001120726/15 A RU2001120726/15 A RU 2001120726/15A RU 2001120726 A RU2001120726 A RU 2001120726A RU 2227749 C2 RU2227749 C2 RU 2227749C2
Authority
RU
Russia
Prior art keywords
group
alkyl
aryl
aralkyl
cyclic
Prior art date
Application number
RU2001120726/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2001120726A (ru
Inventor
Марк Д. ЭРИОН (US)
Марк Д. ЭРИОН
ПУЛЬЕ Пауль ван (US)
ПУЛЬЕ Пауль Ван
Original Assignee
Метабэйсис Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метабэйсис Терапьютикс, Инк. filed Critical Метабэйсис Терапьютикс, Инк.
Publication of RU2001120726A publication Critical patent/RU2001120726A/ru
Application granted granted Critical
Publication of RU2227749C2 publication Critical patent/RU2227749C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
RU2001120726/15A 1998-12-24 1999-12-22 Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета RU2227749C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11471898P 1998-12-24 1998-12-24
US60/114,718 1998-12-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2003132054/14A Division RU2003132054A (ru) 1998-12-24 2003-10-31 Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета

Publications (2)

Publication Number Publication Date
RU2001120726A RU2001120726A (ru) 2003-04-20
RU2227749C2 true RU2227749C2 (ru) 2004-04-27

Family

ID=22357016

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2001120726/15A RU2227749C2 (ru) 1998-12-24 1999-12-22 Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета
RU2003132054/14A RU2003132054A (ru) 1998-12-24 2003-10-31 Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2003132054/14A RU2003132054A (ru) 1998-12-24 2003-10-31 Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета

Country Status (25)

Country Link
EP (1) EP1143955B1 (https=)
JP (1) JP2003515523A (https=)
KR (3) KR20070046210A (https=)
CN (3) CN1714866A (https=)
AT (1) ATE300288T1 (https=)
AU (1) AU771039B2 (https=)
BR (1) BR9917005A (https=)
CA (1) CA2354053A1 (https=)
CZ (1) CZ20012353A3 (https=)
DE (1) DE69926400T2 (https=)
DK (1) DK1143955T3 (https=)
ES (1) ES2246586T3 (https=)
HK (1) HK1046863B (https=)
HU (1) HUP0402506A3 (https=)
ID (1) ID30237A (https=)
IL (2) IL143569A0 (https=)
MX (1) MXPA01006511A (https=)
NO (1) NO20013115L (https=)
NZ (1) NZ512219A (https=)
PL (1) PL352756A1 (https=)
PT (1) PT1143955E (https=)
RU (2) RU2227749C2 (https=)
SK (1) SK9172001A3 (https=)
WO (1) WO2000038666A2 (https=)
ZA (1) ZA200105016B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2328308C2 (ru) * 2000-07-06 2008-07-10 Метабэйсис Терапьютикс, Инк. Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
KR100818845B1 (ko) 1998-09-09 2008-04-01 메타베이시스 테라퓨틱스, 인크. 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
AU784370B2 (en) * 1999-12-22 2006-03-23 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
JP2003525944A (ja) 2000-03-08 2003-09-02 メタバシス・セラピューティクス・インコーポレイテッド 新規アリールフルクトース−１，６−ビスホスファターゼ阻害剤
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1340749A4 (en) * 2000-11-17 2007-09-05 Takeda Pharmaceutical ISOXAZOLE DERIVATIVES
EP2223927B1 (en) 2002-05-13 2014-10-15 Metabasis Therapeutics, Inc. Salts of a phosphonic acid based prodrug of PMEA
WO2003095665A2 (en) 2002-05-13 2003-11-20 Metabasis Therapeutics, Inc. Pmea and pmpa cyclic producing synthesis
AU2003264256A1 (en) * 2002-09-04 2004-03-29 Dsm Ip Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
SI1611112T1 (sl) * 2003-02-11 2012-12-31 Vernalis (R&D) Limited Izoksazolne spojine kot inhibitorji vroäśinskih ĺ ok proteinov
JP4638355B2 (ja) * 2003-12-26 2011-02-23 協和発酵キリン株式会社 チアゾール誘導体
JP2008510018A (ja) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規チアゾール阻害物質
BRPI0519006A2 (pt) * 2004-12-13 2008-12-23 Daiichi Sankyo Co Ltd uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
EP1825854A1 (en) * 2004-12-15 2007-08-29 Daiichi Sankyo Company, Limited MEDICINAL COMPOSITION CONTAINING FBPase INHIBITOR
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Combined drug for treating diabetes
EP1894930A4 (en) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US9631825B2 (en) 2012-12-18 2017-04-25 Nortek Air Solutions, Llc Air filter assembly
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CN105481896A (zh) * 2015-12-03 2016-04-13 浙江大学 一种地马格列的制备方法
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
JPH03157377A (ja) * 1988-11-18 1991-07-05 Takeda Chem Ind Ltd チオ尿素誘導体及びａｇｅ生成阻害剤
DE69014562T2 (de) * 1989-01-24 1995-06-22 Gensia Pharma Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6284748B1 (en) * 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
DE69819311T2 (de) * 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
US6054587A (en) * 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2328308C2 (ru) * 2000-07-06 2008-07-10 Метабэйсис Терапьютикс, Инк. Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета

Also Published As

Publication number Publication date
PL352756A1 (en) 2003-09-08
KR100689943B1 (ko) 2007-03-08
EP1143955B1 (en) 2005-07-27
NO20013115D0 (no) 2001-06-21
ZA200105016B (en) 2002-09-19
HK1046863B (zh) 2008-07-25
AU2058300A (en) 2000-07-31
WO2000038666A3 (en) 2001-11-29
CN1350466A (zh) 2002-05-22
SK9172001A3 (en) 2002-04-04
KR20060114724A (ko) 2006-11-07
KR20010099942A (ko) 2001-11-09
DE69926400D1 (de) 2005-09-01
EP1143955A2 (en) 2001-10-17
BR9917005A (pt) 2002-04-02
CN100352505C (zh) 2007-12-05
PT1143955E (pt) 2005-11-30
MXPA01006511A (es) 2004-03-19
IL143569A (en) 2006-06-11
EP1143955A3 (en) 2002-08-28
HUP0402506A2 (hu) 2005-04-28
WO2000038666A2 (en) 2000-07-06
HK1046863A1 (zh) 2003-01-30
IL143569A0 (en) 2002-04-21
CN1714866A (zh) 2006-01-04
DK1143955T3 (da) 2005-11-14
KR20070046210A (ko) 2007-05-02
HUP0402506A3 (en) 2007-05-29
AU771039B2 (en) 2004-03-11
ES2246586T3 (es) 2006-02-16
JP2003515523A (ja) 2003-05-07
NO20013115L (no) 2001-08-24
ID30237A (id) 2001-11-15
DE69926400T2 (de) 2006-05-24
RU2003132054A (ru) 2005-04-20
NZ512219A (en) 2004-12-24
CA2354053A1 (en) 2000-07-06
CZ20012353A3 (cs) 2001-12-12
ATE300288T1 (de) 2005-08-15
CN101164618A (zh) 2008-04-23

Similar Documents

Publication Publication Date Title
RU2227749C2 (ru) Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета
RU2001120726A (ru) Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета
JP2003515523A5 (https=)
US8455544B2 (en) Synthetic triterpenoids and methods of use in the treatment of disease
JP7656574B2 (ja) 甲状腺関連副作用を低下させる方法
EP1240174A2 (en) Novel bisamidate phosphonate prodrugs
AU754488B2 (en) Method for treating diabetes employing an aP2 inhibitor and combination
JP2003519154A5 (https=)
US20130137629A1 (en) Combination treatment for metabolic disorders
RU2006126062A (ru) Композиции и способы для лечения диабета
SK35196A3 (en) Use of thiazolidinedione derivative and related agents
RU2003103436A (ru) Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета
BRPI0808157A2 (pt) Uso de inibidor de trpm5 para regular insulina e a liberação de glp-1
US20080027052A1 (en) Methods for treating cystic kidney disease
EP1906956A2 (en) Use of thiazole derivatives and analogues in disorders caused by free fatty acids
CA3044059A1 (en) Method of treating glycogen storage disease
FR2896157A1 (fr) Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
CA2479222A1 (en) Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
ES2970909T3 (es) Composición farmacéutica para administración nasal que comprende rifampicinas para el tratamiento de la demencia
MXPA02003452A (es) Tratamiento de combinacion de esclerosis multiple (em), otras condiciones de desmielinacion y neuropatia periferica, especialmente neuropatias dolorosas y neuropatia diabetica.
CN101237866A (zh) 噻唑类衍生物和类似物在游离脂肪酸引起的疾病中的应用
KR20080028415A (ko) ＰＰＡＲγ 애고니스트를 함유하는 의약 조성물
JP2005514399A (ja) ＰＰＡＲγアクチベーターの投薬法
JP2004513923A (ja) ある種のインスリン感作剤またはｐｐａｒ−ガンマアゴニストの新規使用
US20040014797A1 (en) Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20111223